MarketCap
Facebook
X
TelegramQuarterly report 2025-Q2
added 08-08-2025
Surmodics Market Cap 2011-2026 | SRDX
As of April 11, 2026 Surmodics has a market cap of $ 608 M
Capitalization is the market value of a company whose shares are traded on the stock exchange. It is calculated by multiplying the market price of a share by the total number of the company's shares. Capitalization indicates volatility, risk, and growth potential. This metric is often used for a quick assessment of a company’s investment profile.[1]
Capitalization is an important indicator for investors and analysts, as it helps determine the size and significance of a company in the stock market. Companies with large capitalization are considered more stable and reliable, as they have more resources and financial power to grow and survive in the market.
This metric can be divided into several categories: small (from 300 million to 2 billion dollars), medium (from 2 to 10 billion dollars), and large (over 10 billion dollars). Companies with different levels of capitalization have their own characteristics and risks, so investors usually take this indicator into account when making investment decisions.
Capitalization can also change over time depending on the share price and the number of shares in circulation. Therefore, it is a dynamic indicator that requires constant monitoring and analysis to make well-informed investment decisions.
Annual Market Cap Surmodics
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 554 M | 480 M | 506 M | 618 M | 705 M | 628 M | 839 M | 386 M | 326 M | 278 M | 294 M | 351 M | 330 M | 190 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 839 M | 190 M | 463 M |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.
Market Cap of other stocks in the Diagnostics research industry
| Issuer | Market Cap | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
221 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Burning Rock Biotech Limited
BNR
|
2.95 B | $ 15.85 | -2.49 % | $ 171 M |  China |
 |
Aspira Women's Health
AWH
|
45.4 M | - | -6.19 % | $ 10.5 M |  USA |
 |
Agilent Technologies
A
|
42 B | $ 115.06 | -0.29 % | $ 35 B | USA |
 |
Biocept
BIOC
|
5.93 M | - | -13.05 % | $ 7.29 M | USA |
 |
BioNano Genomics
BNGO
|
7.95 M | $ 1.13 | -2.59 % | $ 6.15 M | USA |
 |
Chembio Diagnostics
CEMI
|
12.6 M | - | 0.22 % | $ 16.8 M | USA |
 |
DermTech
DMTK
|
42.4 M | - | -11.32 % | $ 2.94 M | USA |
 |
CareDx, Inc
CDNA
|
993 M | $ 16.05 | -3.83 % | $ 855 M | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
421 M | - | - | $ 562 M |  Britain |
|
Akumin
AKU
|
75.1 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Enzo Biochem
ENZ
|
57.5 K | - | -8.98 % | $ 14.8 K | USA |
 |
Interpace Biosciences
IDXG
|
7.34 M | $ 2.3 | - | $ 10.2 M | USA |
 |
Exact Sciences Corporation
EXAS
|
19.5 B | - | - | $ 19.8 B | USA |
 |
Co-Diagnostics
CODX
|
5.85 M | $ 4.4 | 101.83 % | $ 5.85 M | USA |
 |
Accelerate Diagnostics
AXDX
|
40.3 M | - | -61.36 % | $ 2.46 M | USA |
 |
Castle Biosciences
CSTL
|
709 M | $ 23.13 | -1.28 % | $ 642 M | USA |
 |
Global Cord Blood Corporation
CO
|
243 M | - | - | $ 399 M | China |
 |
Fluidigm Corporation
FLDM
|
481 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
9.22 B | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
1.54 B | - | 0.12 % | $ 80.1 M | China |
 |
Charles River Laboratories International
CRL
|
7.69 B | $ 175.65 | 0.06 % | $ 8.71 B | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
7.87 B | - | - | $ 10.7 B | USA |
 |
Medpace Holdings
MEDP
|
13 B | $ 493.53 | -1.59 % | $ 14.2 B | USA |
 |
Danaher Corporation
DHR
|
150 B | $ 189.61 | -1.7 % | $ 135 B | USA |
 |
Heska Corporation
HSKA
|
844 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
2.99 M | - | -20.0 % | $ 1.06 M | USA |
 |
Illumina
ILMN
|
16.4 B | $ 120.93 | -2.22 % | $ 19.2 B | USA |
 |
Myriad Genetics
MYGN
|
409 M | $ 4.35 | -2.03 % | $ 403 M | USA |
 |
Fulgent Genetics
FLGT
|
467 M | $ 14.43 | -3.93 % | $ 436 M | USA |
 |
NeoGenomics
NEO
|
1.48 B | $ 7.69 | -3.17 % | $ 985 M | USA |
 |
Guardant Health
GH
|
13.4 B | $ 78.6 | -9.83 % | $ 9.85 B | USA |
 |
QIAGEN N.V.
QGEN
|
8.52 B | - | - | $ 10.6 B |  Niderland |
 |
Anixa Biosciences
ANIX
|
104 K | $ 2.69 | -1.82 % | $ 87.3 K | USA |
 |
Biomerica
BMRA
|
7.19 M | $ 2.13 | -0.9 % | $ 4.89 M | USA |
 |
Koninklijke Philips N.V.
PHG
|
30.8 B | $ 28.31 | 0.62 % | $ 20 B | Niderland |
 |
ICON Public Limited Company
ICLR
|
16.6 B | $ 106.81 | 0.1 % | $ 8.81 B |  Irlanda |
 |
Check-Cap Ltd.
CHEK
|
4.33 M | - | - | $ 9.42 M |  Israel |
 |
Laboratory Corporation of America Holdings
LH
|
23.9 B | $ 260.93 | -4.51 % | $ 21.7 B | USA |
 |
Natera
NTRA
|
5.31 B | $ 193.03 | -4.91 % | $ 19 B | USA |
 |
Celcuity
CELC
|
5.37 B | $ 117.14 | -6.02 % | $ 5.48 B | USA |
 |
Lantheus Holdings
LNTH
|
5.12 B | $ 80.59 | -1.03 % | $ 5.44 B | USA |
 |
Senseonics Holdings
SENS
|
351 M | $ 6.68 | 0.15 % | $ 279 M | USA |
 |
Motus GI Holdings
MOTS
|
990 K | - | -34.28 % | $ 263 K | Israel |
 |
Soleno Therapeutics
SLNO
|
2.08 B | $ 52.63 | 0.23 % | $ 2.67 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
23.3 B | $ 191.51 | -3.19 % | $ 21.3 B | USA |
 |
Neogen Corporation
NEOG
|
1.02 B | $ 9.42 | -6.13 % | $ 2.04 B | USA |
 |
ENDRA Life Sciences
NDRA
|
3.66 M | $ 4.94 | -6.97 % | $ 3.89 M | USA |
 |
Neuronetics
STIM
|
81.1 M | $ 1.35 | -2.17 % | $ 89 M | USA |
 |
National Research Corporation
NRC
|
315 M | $ 16.48 | -3.34 % | $ 369 M | USA |